BMRN vs FHN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BMRN · Biomarin Pharmaceutical$56.03 ▼ 0.16%
FHN · First Horizon National$23.04 ▼ 0.35%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BMRN +6.4%
- FHN +8.6%
Head to head
| Metric | BMRN | FHN |
|---|---|---|
| Price | $56.03 | $23.04 |
| Change today | ▼ 0.16% | ▼ 0.35% |
| Market cap | $10.85B | $10.85B |
| Return, 3 months | -18.7% | -8.0% |
| Return, year to date | -5.7% | -1.5% |
| Return, 1 year | +8.9% | +10.0% |
| P/E (TTM) | – | 16.6 |
| P/B | 1.7 | 1.3 |
| P/E percentile vs own 5y | 64th | 99th |
| Dividend yield | – | 2.86% |
| Revenue growth (YoY, latest qtr) | +19.9% | -52.9% |
| Net profit growth (YoY) | -81.4% | -129.7% |
| Gross margin | 76.1% | – |
| Operating margin | 4.4% | – |
| Net margin | 2.1% | -19.4% |
| Return on equity | 1.2% | – |
| Analyst target vs. price | +66.4% | +16.9% |
| Analyst buy share | 78% | 36% |
| RSI (14) | 45 | 45 |
| 30-day volatility | 28.8% | 18.1% |
| Max drawdown, 1 year | -22.6% | -16.5% |
| Trend read | Leaning bullish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BMRN is the largest of the group by market value.
- FHN has returned the most over the past year.
- BMRN is growing revenue fastest.
- BMRN keeps the most profit per dollar of sales.
- FHN has been the calmest stock over the last 30 days.